Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer.

Autor: Brozos-Vázquez E; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain., Lago-Lestón RM; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.; Liquid Biopsy Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain., Covela M; Department of Medical Oncology, Lucus Augusti University Hospital of Lugo (CHULA), 27003 Lugo, Spain., de la Cámara Gómez J; Department of Medical Oncology, University Hospital of Ferrol (CHUF), 15405 Ferrol, Spain., Fernández-Montes A; Department of Medical Oncology, University Hospital Complex of Ourense (CHUO), 32005 Ourense, Spain., Candamio S; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain., Vidal Y; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain., Vázquez F; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain., Abalo A; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.; Liquid Biopsy Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain., López R; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain., Blanco C; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain., Muinelo-Romay L; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.; Liquid Biopsy Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain., Ferreirós-Vidal I; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.; Liquid Biopsy Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain., López-López R; Translational Medical Oncology Group, Oncomet, University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain.; Liquid Biopsy Unit, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain.

Publikováno v: Cancers [Cancers (Basel)] 2023 Jul 12; Vol. 15 (14). Date of Electronic Publication: 2023 Jul 12.

Noninvasive early detection of colorectal cancer by hypermethylation of the LINC00473 promoter in plasma cell-free DNA.

Autor: Ruiz-Bañobre J; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain., Rodriguez-Casanova A; Cancer Epigenomics Laboratory, Epigenomics Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago (IDIS), 15706, Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782, Santiago de Compostela, Spain., Costa-Fraga N; Cancer Epigenomics Laboratory, Epigenomics Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782, Santiago de Compostela, Spain., Bao-Caamano A; Cancer Epigenomics Laboratory, Epigenomics Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782, Santiago de Compostela, Spain., Alvarez-Castro A; Department of Gastroenterology and Hepatology, University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain., Carreras-Presas M; Department of Gastroenterology and Hepatology, University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain., Brozos-Vazquez E; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain., Vidal-Insua Y; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain., Vazquez-Rivera F; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain., Candamio-Folgar S; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain., Mosquera-Presedo M; Cancer Epigenomics Laboratory, Epigenomics Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), 15782, Santiago de Compostela, Spain., Lago-Lestón RM; Liquid Biopsy Analysis Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain., Muinelo-Romay L; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain.; Liquid Biopsy Analysis Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain., Vázquez-Bueno JÁ; Department of Pathology, Complejo Hospitalario Universitario de Ferrol (SERGAS), 15405, Ferrol, Spain., Sanz-Pamplona R; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), 08907, Barcelona, Spain.; Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), 08907, Barcelona, Spain.; Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), 28029, Madrid, Spain., Moreno V; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), 08907, Barcelona, Spain.; Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), 08907, Barcelona, Spain.; Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), 28029, Madrid, Spain.; Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, 08907, Barcelona, Spain., Goel A; Center for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott and White Research Institute, Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.; Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Monrovia, CA, USA.; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Castillo L; Advanced Marker Discovery (AMADIX), 47004, Valladolid, Spain., Martin AC; Advanced Marker Discovery (AMADIX), 47004, Valladolid, Spain., Arroyo R; Advanced Marker Discovery (AMADIX), 47004, Valladolid, Spain., Esteller M; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain.; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Institucio Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain., Crujeiras AB; Epigenomics in Endocrinology and Nutrition Group, Epigenomics Unit, Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red Fisiopatología de La Obesidad y Nutrición (CIBERobn), ISCIII, 28029, Madrid, Spain., López-López R; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain. rafael.lopez.lopez@sergas.es.; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain. rafael.lopez.lopez@sergas.es.; Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago (IDIS), 15706, Santiago de Compostela, Spain. rafael.lopez.lopez@sergas.es., Díaz-Lagares A; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, 28029, Madrid, Spain. angel.diaz.lagares@sergas.es.; Cancer Epigenomics Laboratory, Epigenomics Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), 15706, Santiago de Compostela, Spain. angel.diaz.lagares@sergas.es.

Publikováno v: Clinical epigenetics [Clin Epigenetics] 2022 Jul 09; Vol. 14 (1), pp. 86. Date of Electronic Publication: 2022 Jul 09.

Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab.

Autor: Mondelo-Macía P; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.; Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain., García-González J; Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain.; Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Santiago de Compostela, Spain., León-Mateos L; Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain.; Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Santiago de Compostela, Spain., Anido U; Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain.; Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain., Aguín S; Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain.; Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain., Abdulkader I; Department of Pathology, Complexo Hospital Universitario de Santiago de Compostela (SERGAS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Sánchez-Ares M; Department of Pathology, Complexo Hospital Universitario de Santiago de Compostela (SERGAS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Abalo A; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain., Rodríguez-Casanova A; Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.; Roche-CHUS Joint Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain., Díaz-Lagares Á; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Santiago de Compostela, Spain.; Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain., Lago-Lestón RM; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain., Muinelo-Romay L; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Santiago de Compostela, Spain., López-López R; Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain.; Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Santiago de Compostela, Spain., Díaz-Peña R; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Santiago de Compostela, Spain.

Publikováno v: Molecular oncology [Mol Oncol] 2021 Nov; Vol. 15 (11), pp. 2923-2940. Date of Electronic Publication: 2021 Sep 23.

Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer.

Autor: Abreu M; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain., Cabezas-Sainz P; Department of Genetics, University of Santiago de Compostela, Campus de Lugo, 27002 Lugo, Spain., Alonso-Alconada L; Nasasbiotech, S.L., Canton Grande 3, 15003 A Coruña, Spain., Ferreirós A; Nasasbiotech, S.L., Canton Grande 3, 15003 A Coruña, Spain., Mondelo-Macía P; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain., Lago-Lestón RM; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain., Abalo A; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain., Díaz E; Fundación MD Anderson Internacional, C/Gómez Hemans 2, 28033 Madrid, Spain., Palacios-Zambrano S; MD Anderson Cancer Center, C/Arturo Soria 270, 28029 Madrid, Spain., Rojo-Sebastian A; Fundación MD Anderson Internacional, C/Gómez Hemans 2, 28033 Madrid, Spain., López-López R; Translational Medical Oncology (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain., Sánchez L; Department of Genetics, University of Santiago de Compostela, Campus de Lugo, 27002 Lugo, Spain., Moreno-Bueno G; Fundación MD Anderson Internacional, C/Gómez Hemans 2, 28033 Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.; Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas 'Alberto Sols' (CSIC-UAM), IdiPaz, Arzobispo Morcillo 4, 28029 Madrid, Spain., Muinelo-Romay L; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.; Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas 'Alberto Sols' (CSIC-UAM), IdiPaz, Arzobispo Morcillo 4, 28029 Madrid, Spain.

Publikováno v: Cells [Cells] 2020 May 14; Vol. 9 (5). Date of Electronic Publication: 2020 May 14.

Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next‐generation sequencing panel: A preliminary study.

Autor: Rapado‐González, Óscar^1,2,3,4 (AUTHOR), Brea‐Iglesias, Jenifer⁵ (AUTHOR), Rodríguez‐Casanova, Aitor^2,6,7,8 (AUTHOR), Bao‐Caamano, Aida^2,6,8 (AUTHOR), López‐Cedrún, José‐Luis⁹ (AUTHOR), Triana‐Martínez, Gabriel¹⁰ (AUTHOR), Díaz‐Peña, Roberto^11,12 (AUTHOR), Santos, María Arminda^1,13 (AUTHOR), López‐López, Rafael^2,4,14 (AUTHOR), Muinelo‐Romay, Laura^2,3,4 (AUTHOR), Martínez‐Fernández, Mónica⁵ (AUTHOR), Díaz‐Lagares, Ángel^2,4,6 (AUTHOR), Suárez‐Cunqueiro, María Mercedes^1,2,4,14 (AUTHOR) mariamercedes.suarez@usc.es

Publikováno v: Cancer Medicine. Mar2023, Vol. 12 Issue 6, p6615-6622. 8p.